Avenue Therapeutics, Inc.
ATXI OTC
SEC CIK 1644963
Follow Avenue Therapeutics
Weekly email: filings, results, news
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$690K
−306% vs same quarter last year
EPS, diluted
−$0.21
−290.9% vs same quarter last year
Operating cash flow
−$475K
−169.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$2.9M |
| FY24 | −$11.7M |
| FY23 | −$10.5M |
| FY22 | −$3.6M |
| FY21 | −$3.7M |
| FY20 | −$5.2M |
| FY19 | −$25.9M |
| FY18 | −$21.5M |
| FY17 | −$12.3M |
| FY16 | −$3.2M |
| FY15 | - |
News
No stories filed under Avenue Therapeutics yet - coverage appears here as the news feed clusters it.